RPL22L1 and colorectal carcinoma: In doing so, we focused on chemoresistance, since 5-FU-based chemotherapy remains a mainstay in the treatment of CRC and 2 of the 4 deceased RPL22L1 high patients in our cohort failed 5-FU based therapy.